Showing results (131-140 of 167) with videos related to

Sort By:
Pageof 17
BJU International|July 17, 2021
'Pain-free TRUS B': a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501)Dickon Hayne, Jeremy Grummet, David Espinoza, et al.
The Lancet. Oncology|August 2, 2025
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trialLouise Emmett, Nathan Papa, Shalini Subramaniam, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 28, 2022
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit StudyYeh Chen Lee, Madeleine T King, Rachel L O'Connell, et al.
JAMA Oncology|September 17, 2020
Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical TrialSrikala S Sridhar, Normand Blais, Ben Tran, et al.
Nature Cancer|April 15, 2026
Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trialLouise Emmett, Mina Swiha, Nathan Papa, et al.
Nature Medicine|May 27, 2025
Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trialEdmond M Kwan, Sarah W S Ng, Sofie H Tolmeijer, et al.
The Lancet. Oncology|July 3, 2021
The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology researchPriya Ranganathan, Girish Chinnaswamy, Manju Sengar, et al.
Gynecologic Oncology|June 19, 2022
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancerRachel Campbell, Daniel S J Costa, Martin R Stockler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2020
Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup TrialTim Eisen, Eleni Frangou, Bhavna Oza, et al.
Cancers|October 13, 2021
Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate CancerHui-Ming Lin, Nicole Yeung, Jordan F Hastings, et al.
Pageof 17